T. E. Eroglu, M. Blom, P. Souverein, A. Boer, H. Tan
{"title":"非心脏去极化阻断药物与社区院外心脏骤停风险增加有关","authors":"T. E. Eroglu, M. Blom, P. Souverein, A. Boer, H. Tan","doi":"10.22541/au.163281221.16214220/v1","DOIUrl":null,"url":null,"abstract":"Aim Depolarization-blocking drugs (DB-drugs) used for cardiac disease\nincrease the risk of cardiac arrhythmia (ventricular\ntachycardia/ventricular fibrillation[VT/VF]) and out-of-hospital\ncardiac arrest (OHCA) in specific patient groups. However, it is unknown\nwhether drugs for non-cardiac disease that block cardiac depolarization\nas off-target effect increase the risk of OHCA on a population level.\nTherefore, we aimed to investigate OHCA-risk of non-cardiac DB-drugs in\nthe community. Methods We conducted a population-based case-control\nstudy. We included OHCA-cases from an Emergency Medical Services\nattended OHCA-registry in the Netherlands (ARREST:2009-2018), and\nage/sex/OHCA-date matched non-OHCA-controls. We calculated adjusted odds\nratios (ORadj) of use of non-cardiac DB-drugs for OHCA, using\nconditional logistic regression. Stratified analyses were performed\naccording to first-registered rhythm (VT/VF or non-VT/VF), sex and age\n(≤50, 50-70, or ≥70 years). Results We included 5,473 OHCA-cases of whom\n427 (7.8%) used non-cardiac DB-drugs, and 21,866 non-OHCA-controls of\nwhom 835 (3.8%) used non-cardiac DB-drugs, and found that non-cardiac\nDB-drug use was associated with increased OHCA-risk when compared to\nno-use (ORadj1.6[95%-CI:1.4-1.9]). Stratification by first-recorded\nrhythm revealed that this applied to OHCA with non-VT/VF (asystole)\n(ORadj2.5[95%-CI:2.1-3.0]), but not with VT/VF\n(ORadj1.0[95%-CI:0.8-1.2];P-value interaction<0.001). The\nrisk was higher in women (ORadj 1.8[95%-CI:1.5-2.2] than in men\n(ORadj1.5[95%-CI:1.2-1.8];P-value interaction=0.030) and at younger\nage\n(ORadj≥70yrs1.4[95%-CI:1.2-1.7];ORadj50-70yrs1.7[95%-CI:1.4-2.1];ORadj≤50yrs3.2[95%-CI:2.1-5.0];P-value\ninteraction<0.001). Conclusions Use of non-cardiac DB-drugs is\nassociated with increased OHCA-risk in the general population. This\nincreased risk occurred in patients in whom non-VT/VF was the\nfirst-registered rhythm, and it occurred in both sexes, but more\nprominently among women, and more strongly in younger patients (≤50\nyears).","PeriodicalId":74431,"journal":{"name":"Pharmacoepidemiology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Non-cardiac depolarization-blocking drugs are associated with increased risk of out-of-hospital cardiac arrest in the community\",\"authors\":\"T. E. Eroglu, M. Blom, P. Souverein, A. Boer, H. Tan\",\"doi\":\"10.22541/au.163281221.16214220/v1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim Depolarization-blocking drugs (DB-drugs) used for cardiac disease\\nincrease the risk of cardiac arrhythmia (ventricular\\ntachycardia/ventricular fibrillation[VT/VF]) and out-of-hospital\\ncardiac arrest (OHCA) in specific patient groups. However, it is unknown\\nwhether drugs for non-cardiac disease that block cardiac depolarization\\nas off-target effect increase the risk of OHCA on a population level.\\nTherefore, we aimed to investigate OHCA-risk of non-cardiac DB-drugs in\\nthe community. Methods We conducted a population-based case-control\\nstudy. We included OHCA-cases from an Emergency Medical Services\\nattended OHCA-registry in the Netherlands (ARREST:2009-2018), and\\nage/sex/OHCA-date matched non-OHCA-controls. We calculated adjusted odds\\nratios (ORadj) of use of non-cardiac DB-drugs for OHCA, using\\nconditional logistic regression. Stratified analyses were performed\\naccording to first-registered rhythm (VT/VF or non-VT/VF), sex and age\\n(≤50, 50-70, or ≥70 years). Results We included 5,473 OHCA-cases of whom\\n427 (7.8%) used non-cardiac DB-drugs, and 21,866 non-OHCA-controls of\\nwhom 835 (3.8%) used non-cardiac DB-drugs, and found that non-cardiac\\nDB-drug use was associated with increased OHCA-risk when compared to\\nno-use (ORadj1.6[95%-CI:1.4-1.9]). Stratification by first-recorded\\nrhythm revealed that this applied to OHCA with non-VT/VF (asystole)\\n(ORadj2.5[95%-CI:2.1-3.0]), but not with VT/VF\\n(ORadj1.0[95%-CI:0.8-1.2];P-value interaction<0.001). The\\nrisk was higher in women (ORadj 1.8[95%-CI:1.5-2.2] than in men\\n(ORadj1.5[95%-CI:1.2-1.8];P-value interaction=0.030) and at younger\\nage\\n(ORadj≥70yrs1.4[95%-CI:1.2-1.7];ORadj50-70yrs1.7[95%-CI:1.4-2.1];ORadj≤50yrs3.2[95%-CI:2.1-5.0];P-value\\ninteraction<0.001). Conclusions Use of non-cardiac DB-drugs is\\nassociated with increased OHCA-risk in the general population. This\\nincreased risk occurred in patients in whom non-VT/VF was the\\nfirst-registered rhythm, and it occurred in both sexes, but more\\nprominently among women, and more strongly in younger patients (≤50\\nyears).\",\"PeriodicalId\":74431,\"journal\":{\"name\":\"Pharmacoepidemiology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22541/au.163281221.16214220/v1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22541/au.163281221.16214220/v1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Non-cardiac depolarization-blocking drugs are associated with increased risk of out-of-hospital cardiac arrest in the community
Aim Depolarization-blocking drugs (DB-drugs) used for cardiac disease
increase the risk of cardiac arrhythmia (ventricular
tachycardia/ventricular fibrillation[VT/VF]) and out-of-hospital
cardiac arrest (OHCA) in specific patient groups. However, it is unknown
whether drugs for non-cardiac disease that block cardiac depolarization
as off-target effect increase the risk of OHCA on a population level.
Therefore, we aimed to investigate OHCA-risk of non-cardiac DB-drugs in
the community. Methods We conducted a population-based case-control
study. We included OHCA-cases from an Emergency Medical Services
attended OHCA-registry in the Netherlands (ARREST:2009-2018), and
age/sex/OHCA-date matched non-OHCA-controls. We calculated adjusted odds
ratios (ORadj) of use of non-cardiac DB-drugs for OHCA, using
conditional logistic regression. Stratified analyses were performed
according to first-registered rhythm (VT/VF or non-VT/VF), sex and age
(≤50, 50-70, or ≥70 years). Results We included 5,473 OHCA-cases of whom
427 (7.8%) used non-cardiac DB-drugs, and 21,866 non-OHCA-controls of
whom 835 (3.8%) used non-cardiac DB-drugs, and found that non-cardiac
DB-drug use was associated with increased OHCA-risk when compared to
no-use (ORadj1.6[95%-CI:1.4-1.9]). Stratification by first-recorded
rhythm revealed that this applied to OHCA with non-VT/VF (asystole)
(ORadj2.5[95%-CI:2.1-3.0]), but not with VT/VF
(ORadj1.0[95%-CI:0.8-1.2];P-value interaction<0.001). The
risk was higher in women (ORadj 1.8[95%-CI:1.5-2.2] than in men
(ORadj1.5[95%-CI:1.2-1.8];P-value interaction=0.030) and at younger
age
(ORadj≥70yrs1.4[95%-CI:1.2-1.7];ORadj50-70yrs1.7[95%-CI:1.4-2.1];ORadj≤50yrs3.2[95%-CI:2.1-5.0];P-value
interaction<0.001). Conclusions Use of non-cardiac DB-drugs is
associated with increased OHCA-risk in the general population. This
increased risk occurred in patients in whom non-VT/VF was the
first-registered rhythm, and it occurred in both sexes, but more
prominently among women, and more strongly in younger patients (≤50
years).